Chiozzi, Paola
Sarti, Alba Clara
Sanz, Juana M.
Giuliani, Anna Lisa
Adinolfi, Elena
Vultaggio-Poma, Valentina
Falzoni, Simonetta
Di Virgilio, Francesco http://orcid.org/0000-0003-3566-1362
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG 16812, IG 13025, IG 18581)
European Cooperation in Science and Technology (BM1406)
Article History
Received: 17 January 2019
Accepted: 11 April 2019
First Online: 24 April 2019
Competing Interests
: F.D.V. is a member of the Scientific Advisory Board of Biosceptre Ltd, a UK-based Company involved in the development of P2X7-targeted antibodies, and has an ongoing collaboration with Ablynx, a Belgian Company involved in the development of P2X7R-targeted nanobodies. Other Authors declare no conflict of interest.